Skip to main content
OpenTrials
Completed

NCT Number: NCT00058591

Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)

Severe chronic active Epstein-Barr virus (SCAEBV) is a rare Epstein-Barr virus (EBV or commonly known as mono or the kissing disease) associated disorder. This disorder may cause chronic tiredness and fevers and sometimes be complicated by life threatening problems such as multi-organ failure, chronic (ongoing) pneumonia, and lymphoproliferative diseases (diseases involving the lymph nodes which could eventually show up as leukemia or a tumor). The reasons for the body's inability to control the EBV infection are still unknown and no effective treatment is currently available.

This research study uses Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTLs). We want to see if we can grow special white blood cells, called T cells, that have been trained to kill EBV infected cells in the laboratory and see if these cells may help control the EBV infection when given back to the patient.

The purpose of this study is to find the largest safe dose of EBV specific CTLs, to learn what the side effects are, and to see whether this therapy might help the body fight off the SCAEBV infection.

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Texas Children's Hospital, Houston, Texas, United States

Loading trial locations.

About this study

Ten to sixty ml (2-12 teaspoons) of blood will be collected from the patient which we use to grow the T cells. These T cells are then stimulated with EBV infected cells (which have been treated with radiation so that they cannot grow). This stimulation trains the T cells to kill EBV infected cells. We then test the T cells to make sure that they kill the EBV infected cells.

Therapy can take place in one of the specifically designated outpatient clinics so hospital admission is not required. First, patients will be given doses of Tylenol (for any aches/pains) and Benadryl (for any minor allergic reactions such as itching/rash). Next, the T cells will be injected into a vein over a 10 minute period. Patients will be closely watched for any side effects.

If a patient shows some response to the treatment they may receive up to three additional T cell injections at three month intervals. Patients will need to be seen every other week in the clinic for six weeks after the injection. Following that, patients will either be seen in the clinic or contacted by one of the research staff working on this study, once a month for one year.

To learn more about the way the T cells are working and how long they last in the body, an extra 40 mls(8 teaspoonfuls) of blood will be taken at these visits. Additionally, 3 mls (1/2 teaspoonful) of blood will be taken prior to the infusion and monthly thereafter to conduct a CBC (a test to look at the components of the blood).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients must have severe chronic EBV infection as manifested by 6 months of symptoms Either elevated peripheral blood EBV DNA (>4000 genomes per ug PBMC DNA) or free EBV DNA in serum or CSF or VCA antibody titer > 1/640
  • Seronegative for HIV
  • Not on investigational agents in the last 4 weeks
  • Signed informed consent obtained from patient/guardian
  • CTLs available
  • Performance status; Karnofsky >60
  • Creatinine < 3X normal
  • Bilirubin < 5X normal
  • Normal electrolytes, calcium, phosphorus, nutritional status
  • Females with child-bearing potential must utilize effective birth control.

Exclusion criteria

  • Patients with a severe intercurrent infection
  • Patients that recently received high dose steroids within the last week or other immunosuppressive drugs within a week (or longer as indicated by the half life of the agent)
  • Patients with life expectancy of less than 6 weeks
  • Pregnant or lactating females

Treatment and study plan

Intravenous injection of EBV specific CTLs

Biological

The dose levels for this study are as follows:

Level Dose

  • 2 x 107 CTLs/m2
  • 5 x 107 CTLs/m2
  • 1 x 108 CTLs/m2

If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals.

Primary outcomes

  1. to determine the safety of intravenous injections of autologous EBV specific cytotoxic T cell lines in individuals with severe chronic EBV infection

    Time frame: 1 yr

Secondary outcomes

  1. determine antiviral and immunological efficacy of intravenous injections of CTLs in these patients

    Time frame: 1 yr

  2. assess the clinical effects of these injections

    Time frame: 1 yr

Sponsors and collaborators

Lead sponsor

Baylor College of Medicine

Other

Collaborators

  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • The Methodist Hospital Research Institute

Registry information

Official study title

Autologous EBV Specific CTLs for Therapy of Severe Chronic EBV Infection

Acronym: SCAEBV

Important dates

Study start
2000
Primary completion
2008
Study completion
2008
First posted
Apr 9, 2003
Registry last updated
Jan 18, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.